Bivalirudin in percutaneous coronary intervention

American Journal of Health-System Pharmacy

Volumn 60, Issue 18, 2003, Pages 1841-1849

  Caron, Michael F ^a,b   McKendall, George R ^c,d  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c RIH   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Angioplasty; Anticoagulants; Bivalirudin; Blood levels; Costs; Dosage; Drug administration; Drug comparisons; Drug interactions; Excretion; Half life; Heparin; Mechanism of action; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Toxicity

Indexed keywords

CYTOCHROME P450 ISOENZYME; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 2642561477     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.18.1841     Document Type: Review

References (39)

1. Lauer MA, Karweit JA, Cascade EF et al. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol. 2002; 89:924-9.
2. American Heart Association. 2003 heart and stroke statistical update. www.americanheart.org/presenter.jhtml?identifier=3000090 (accessed 2003 Jan 9).
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361:13-20.
4. TCTMD. News from major meeting/DANAMI-2 supports primary PTCA even with 3 hours transport time. www.tctmd.com/meeting-news/one.html?news_item_id=2539 (accessed 2002 Jan 28).
5. TCTMD. News from major meeting/PRAGUE-2 shows transport for PCI to be superior to thrombolysis in AMI. www.tctmd.com/meeting-news/one.html? news_item_id=2724 (accessed 2002 Jan 28).
6. Fuster V, Badimon L, Badimon JJ et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 326:242-50.
7. Nappi J. The biology of thrombin in acute coronary syndromes. Pharmacotherapy. 2002; 22(suppl):90S-6S.
8. Angiomax package insert. Parsippany, NJ: The Medicines Company; 2002.
9. Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995; 333:764-9.
10. Bittl JA, Chaitman BR, Feit F et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001; 142:952-9.
11. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA. 2003; 289:853-63.
12. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry. 1994; 33:14807-14.
13. Hirsh J, Warkentin TE, Shaughness SG et al. Heparin and low-molecular weight heparins: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119(suppl):64S-94S.
14. Weitz JI, Hudoba M, Massel D et al. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990; 86:385-91.
15. Wittkowsky AK. The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy. 2002; 22(suppl):97S-104S.
16. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002; 22(suppl):105S-11S.
17. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation. 2002; 105:1004-11.
18. Caron MF, McBride B, Kalus JS et al. Fundamental concepts in pharmacokinetics and pharmacodynamics of antithrombotic agents. In: Becker R, Harrington R, eds. The practice of clinical, interventional and investigational thrombocardiology. In press.
19. Fox I, Dawson A, Loynds P et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993; 69:157-63.
20. Robson R, White H, Aylward P et al. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002; 71:433-9.
21. Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol. 2000; 12(suppl F):F41-52.
22. Topol EJ, Bonan R, Jewitt D et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation. 1993; 87:1622-9.
23. Lincoff AM, Kleiman NS, Kottke-Marchant K et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial. Am Heart J. 2002; 143:847-53.
24. Lincoff AM, Bittl JA, Kleiman NS. The REPLACE-1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. J Am Coll Cardiol. 2002; 39(suppl A):16A. Abstract.
25. The EPISTENT investigators. Randomised placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998; 352:87-92.
26. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356:2037-44.
27. Siegel JP. Equivalence and noninferiority trials. Am Heart J. 2000; 139(suppl):S166-70.
28. Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344:1888-94.
29. The INJECT investigators. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995; 346:329-36.
30. Rao AK, Pratt C, Berke A et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1998; 11:1-11.
31. Kereiakes DJ, Lincoff AM, Anderson KM et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 2002; 90:628-30.
32. Antman EM, McCabe CH, Braunwald E et al. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. Am Heart J. 2002; 142:229-34.
33. White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001; 358:1855-63.
34. Kelton JG, Smith JW, Warkentin TE et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994; 83:3232-9.
35. The Heart.org Cardiology Online Heartwire. REPLACE-2 results. Will bivalirudin replace GP IIb/IIIa blockers in PCI? www.theheart.org (accessed 2003 May 29).
36. Cohen HE, Chi JC, Sifton DW et al., eds. Red book. Montvale, NJ: Thomson Medical Economics; 2002.
37. Cohen DJ, on behalf of the REPLACE-2 Investigators. Presentation delivered at the American College of Cardiology Meeting. Chicago, IL; 2002 Mar 29.
38. The Heart.org Cardiology Online Heartwire. What does the future hold for bivalirudin? www.theheart.org/index.cfm (accessed 2003 Jan 9).
39. Smith SC Jr, Dove JT, Jacobs AK et al. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2001; 37:2239i-lxvi.